Syndax Pharmaceuticals, Inc. (SNDX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Syndax Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Syndax Pharmaceuticals, Inc. (SNDX) has returned 11.19% so far this year and 90.15% over the past 12 months. Over the last ten years, SNDX has returned 5.95% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Mar 3, 2016, SNDX's average daily return is +0.13%, while the average monthly return is +2.24%. At this rate, your investment would double in approximately 2.6 years.

Historically, 53% of months were positive and 47% were negative. The best month was Aug 2025 with a return of +64.6%, while the worst month was Oct 2018 at -40.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.

On a daily basis, SNDX closed higher 49% of trading days. The best single day was Apr 28, 2020 with a return of +69.4%, while the worst single day was Apr 20, 2021 at -30.8%.

Syndax Pharmaceuticals, Inc. has an annualized alpha of 18.26%, beta of 1.10, and R² of 0.08 versus S&P 500 Index. Calculated based on daily prices since March 04, 2016.

• This stock participated in 71.50% of S&P 500 Index downside but only 57.17% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.08 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

SNDX ranks 78 for risk / return — better than 78% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Syndax Pharmaceuticals, Inc. (SNDX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Syndax Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Syndax Pharmaceuticals, Inc. was 78.98%, occurring on Dec 24, 2018. Recovery took 337 trading sessions.

The current Syndax Pharmaceuticals, Inc. drawdown is 19.39%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Syndax Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Syndax Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.